DLA Piper advises Quantum-Si in pricing of US$50 million of common stock and New Equity Distribution Agreement worth US$75 million

DLA Piper advised Quantam-Si Incorporated, The Protein Sequencing Company™, a biotechnology company focused on the growing field of proteomics, in two separate transactions: the pricing of US$50 registered direct offering of common stock, and the entering into an equity distribution agreement.

The company entered into securities purchase agreements with certain institutional investors for the purchase and sale of 15,625,000 shares of common stock at a purchase price of US$3.20 per share, resulting in gross proceeds of approximately US$50 million. The net proceeds from the offering will be used for working capital and general corporate purposes.

Additionally, the company previously entered into the agreement with Canaccord Genuity LLC, a global, full-service investment bank, to sell up to US$75 million of its Class A common stock through an ‘at the market offering’ program.

The DLA Piper team was led by partner Larry Nishnick (San Diego) and included valuable support from associates Biana LaCaille (Seattle) and Melody Lilazy (San Diego).

With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm is an active advisor in public company securities offerings. In addition to these capital markets transactions, DLA Piper has been rated number one in global M&A volume for 14 consecutive years, according to Mergermarket, and ranked as a top five most active VC legal advisor in the US and number one in VC, PE and M&A in combined global deal volume according to PitchBook.